Diabetes: Medtronic wins CE Mark for Sentrino continuous glucose monitor
Medical device company Medtronic receives CE Mark approval for its Sentrino continuous glucose management system, the 1st minimally invasive continuous glucose monitoring system specifically designed for use in hospital critical care units.
Medical device giant Medtronic (NYSE:MDT) landed CE Mark approval in the European Union for its Sentrino minimally invasive continuous glucose monitoring system, the 1st device of its kind designed to improve glucose control for critical care patients.
The Sentrino CGM System continuously displays the patient's interstitial glucose value and show real-time trend data to help the patients with glucose control. When the glucose values fall outside the target range, the system provides predictive alarms and alerts, according to a press release.